Consistent with this, we have previously demonstrated, in preclinical models of basal-like breast cancer and malignant melanoma, that CAIX expression is associated with an altered anti-tumour immune response and that its inhibition enhances the efficacy of immune checkpoint blockade [23]. This evidence concerns the gene CA9 and breast carcinoma.